Acute pain management in the older adult is both challenging and rewarding. This review addresses the difficulty with assessment of pain in the older adult, variations in the pain experience of ...
Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med. 2006;144:127-134. Republished with permission. Marian S. Grant, CRNP, Program ...
An increased prevalence of diseases such as pain after surgery, the trauma of acute injuries, as well as accidents creates an enormous need for proper pain management. The demand is further amplified ...
And why might you reach for one over another when you’ve got a headache or some other pain? That’s why we — Raj Punjabi and Noah Michelson, hosts of HuffPost’s “Am I Doing It Wrong?” podcast — asked ...
How does your brain know when you feel pain? How does it know the difference between the soft touch of a feather and a needle prick? And, how does that information get to your body in time to respond?
enabling personalised management. Renal replacement therapy (RRT) is considered in patients with progressive AKI and possibly life-threatening complications of AKI. The spectrum of RRT includes ...
31, 2024 — With its emphasis on opioid overdose prevention, the first guideline for primary care providers from the American Academy of Pediatrics on prescribing opioids for acute pain in ...
Research indicates CBD may play a promising complementary role in pain management, though additional clinical trials are necessary. Continue reading to learn about using CBD to curb pain and the ...
Epigastric pain refers to pain or discomfort below the ribs in your upper abdomen area. Causes range from acute digestive issues like acid reflux to chronic conditions such as esophagitis.
Panels of molecular biomarkers, such as plasma TNFR1 and TNFR2, urinary MCP1, uromodulin, and EGF measured 3 months after AKI have been associated with progression of CKD and cardiovascular events, 29 ...
Developing a robust approach to mitigating the current opioid crisis in the USA will require translating novel evidence-based, neuroscience-informed treatments into clinical care and public policy.